{"title":"评估在Yalgado OUEDRAOGO大学医院肝消化内科监测的慢性乙型肝炎患者的直接费用。","authors":"Karim Ouedraogo, Amadou Oury Toure, Fadima Yaya Bocoum, Djenabou Diallo, Alexandre Delamou, Seni Kouanda","doi":"10.1186/s12876-025-04320-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Chronic viral hepatitis B constitutes a public health problem due to its morbidity, mortality and economic consequences. To date, the direct costs incurred by patients for the treatment of this condition are not well documented. Our study aims to provide evidence on this cost in order to help facilitate patient care and optimize national hepatitis control policies.</p><p><strong>Methodology: </strong>This is a cross-sectional study with analytical aims lasting one month. The study population consisted of patients followed in outpatient consultation in the hepato-gastroenterology department of the Yalgado OUEDRAOGO University Hospital Center (CHU-YO). We conducted a census of patients seen in consultation and meeting the inclusion criteria. Data were collected following direct interviews with patients and review of medical records. The determinants of the direct cost of chronic viral hepatitis B management were identified using linear regression.</p><p><strong>Results: </strong>The mean direct cost incurred by patients on tenofovir treatment during the first three years of follow-up was 538,293 XOF with a 95% CI [466,005-610,581] and a standard deviation of 35,739 XOF. The mean direct cost incurred by patients without tenofovir treatment during the first three years of follow-up was 359,664 XOF (≈ 611.4 USD) with a 95% CI [331,276-388,052] XOF and a standard deviation of 14,323 XOF . The mean non-medical direct cost during the first three years of follow-up was 30,037 XOF (≈ 52.14 USD) with a 95% CI [22,498-37,575] XOF and a standard deviation of 3,815 XOF.</p><p><strong>Conclusion: </strong>The cost of chronic viral hepatitis B treatment at CHU-YO is very high compared to patients' income. Laboratory and imaging tests constitute the bulk of patient care expenses. To facilitate patient monitoring in order to avoid or delay the occurrence of complications, it is necessary to implement financial protection mechanisms in health.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"717"},"PeriodicalIF":2.5000,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12513083/pdf/","citationCount":"0","resultStr":"{\"title\":\"Evaluation of the direct cost of chronic viral hepatitis B in patients monitored at the hepato-gastroenterology department of the Yalgado OUEDRAOGO University Hospital.\",\"authors\":\"Karim Ouedraogo, Amadou Oury Toure, Fadima Yaya Bocoum, Djenabou Diallo, Alexandre Delamou, Seni Kouanda\",\"doi\":\"10.1186/s12876-025-04320-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Chronic viral hepatitis B constitutes a public health problem due to its morbidity, mortality and economic consequences. To date, the direct costs incurred by patients for the treatment of this condition are not well documented. Our study aims to provide evidence on this cost in order to help facilitate patient care and optimize national hepatitis control policies.</p><p><strong>Methodology: </strong>This is a cross-sectional study with analytical aims lasting one month. The study population consisted of patients followed in outpatient consultation in the hepato-gastroenterology department of the Yalgado OUEDRAOGO University Hospital Center (CHU-YO). We conducted a census of patients seen in consultation and meeting the inclusion criteria. Data were collected following direct interviews with patients and review of medical records. The determinants of the direct cost of chronic viral hepatitis B management were identified using linear regression.</p><p><strong>Results: </strong>The mean direct cost incurred by patients on tenofovir treatment during the first three years of follow-up was 538,293 XOF with a 95% CI [466,005-610,581] and a standard deviation of 35,739 XOF. The mean direct cost incurred by patients without tenofovir treatment during the first three years of follow-up was 359,664 XOF (≈ 611.4 USD) with a 95% CI [331,276-388,052] XOF and a standard deviation of 14,323 XOF . The mean non-medical direct cost during the first three years of follow-up was 30,037 XOF (≈ 52.14 USD) with a 95% CI [22,498-37,575] XOF and a standard deviation of 3,815 XOF.</p><p><strong>Conclusion: </strong>The cost of chronic viral hepatitis B treatment at CHU-YO is very high compared to patients' income. Laboratory and imaging tests constitute the bulk of patient care expenses. To facilitate patient monitoring in order to avoid or delay the occurrence of complications, it is necessary to implement financial protection mechanisms in health.</p>\",\"PeriodicalId\":9129,\"journal\":{\"name\":\"BMC Gastroenterology\",\"volume\":\"25 1\",\"pages\":\"717\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-10-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12513083/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Gastroenterology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12876-025-04320-0\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12876-025-04320-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
慢性乙型病毒性肝炎由于其发病率、死亡率和经济后果,构成了一个公共卫生问题。迄今为止,患者因治疗这种疾病而产生的直接费用没有很好的记录。我们的研究旨在为这一成本提供证据,以帮助促进患者护理和优化国家肝炎控制政策。方法:这是一项横断面研究,分析目标持续一个月。研究人群包括在Yalgado OUEDRAOGO大学医院中心(CHU-YO)肝消化内科门诊会诊的患者。我们对就诊并符合纳入标准的患者进行了普查。数据是通过与患者直接面谈和查阅医疗记录收集的。使用线性回归确定了慢性乙型肝炎管理直接成本的决定因素。结果:患者在前三年随访期间接受替诺福韦治疗的平均直接成本为538,293 XOF, 95% CI[466,005-610,581],标准差为35,739 XOF。未接受替诺福韦治疗的患者在前三年随访期间的平均直接成本为359664 XOF(≈611.4美元),95% CI [331276 - 388052] XOF,标准差为14323 XOF。前三年随访期间的平均非医疗直接费用为30,037 XOF(≈52.14 USD), 95% CI [22,498-37,575] XOF,标准差为3,815 XOF。结论:CHU-YO治疗慢性乙型肝炎的费用与患者的收入相比非常高。实验室和影像学检查占病人护理费用的大部分。为了便于对患者进行监测,以避免或延迟并发症的发生,有必要实施卫生方面的财务保护机制。
Evaluation of the direct cost of chronic viral hepatitis B in patients monitored at the hepato-gastroenterology department of the Yalgado OUEDRAOGO University Hospital.
Introduction: Chronic viral hepatitis B constitutes a public health problem due to its morbidity, mortality and economic consequences. To date, the direct costs incurred by patients for the treatment of this condition are not well documented. Our study aims to provide evidence on this cost in order to help facilitate patient care and optimize national hepatitis control policies.
Methodology: This is a cross-sectional study with analytical aims lasting one month. The study population consisted of patients followed in outpatient consultation in the hepato-gastroenterology department of the Yalgado OUEDRAOGO University Hospital Center (CHU-YO). We conducted a census of patients seen in consultation and meeting the inclusion criteria. Data were collected following direct interviews with patients and review of medical records. The determinants of the direct cost of chronic viral hepatitis B management were identified using linear regression.
Results: The mean direct cost incurred by patients on tenofovir treatment during the first three years of follow-up was 538,293 XOF with a 95% CI [466,005-610,581] and a standard deviation of 35,739 XOF. The mean direct cost incurred by patients without tenofovir treatment during the first three years of follow-up was 359,664 XOF (≈ 611.4 USD) with a 95% CI [331,276-388,052] XOF and a standard deviation of 14,323 XOF . The mean non-medical direct cost during the first three years of follow-up was 30,037 XOF (≈ 52.14 USD) with a 95% CI [22,498-37,575] XOF and a standard deviation of 3,815 XOF.
Conclusion: The cost of chronic viral hepatitis B treatment at CHU-YO is very high compared to patients' income. Laboratory and imaging tests constitute the bulk of patient care expenses. To facilitate patient monitoring in order to avoid or delay the occurrence of complications, it is necessary to implement financial protection mechanisms in health.
期刊介绍:
BMC Gastroenterology is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of gastrointestinal and hepatobiliary disorders, as well as related molecular genetics, pathophysiology, and epidemiology.